RecruitingPhase 4NCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eli Lilly and Company
- Principal Investigator
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company
- Intervention
- Pirtobrutinib(drug)
- Enrollment
- 150 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2032
Study locations (30)
- Mitchell Cancer Institute, Mobile, Alabama, United States
- Arizona Oncology Associates, P.C. - HOPE, Tucson, Arizona, United States
- Cancer Specialists, LLC, Jacksonville, Florida, United States
- Minnesota Oncology Hematology, P.A., Coon Rapids, Minnesota, United States
- Cayuga Cancer Center, Ithaca, New York, United States
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York, United States
- Oncology Hematology Care Inc, Cincinnati, Ohio, United States
- Texas Oncology - Paris, Fort Worth, Texas, United States
- US Oncology - Texas Oncology, Kyle, Texas, United States
- Liverpool Hospital, Liverpool, Australia
- The Alfred Hospital, Melbourne, Australia
- LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria
- AZ Delta, Roeselare, Belgium
- Princess Margaret Cancer Centre - University Health Network, Toronto, Canada
- Xuanwu Hospital Capital Medical University, Beijing, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07218341 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn
- RECRUITINGPHASE2NCT07221500A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)Nurix Therapeutics, Inc.